<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941952</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01283-48</org_study_id>
    <nct_id>NCT02941952</nct_id>
  </id_info>
  <brief_title>Comparative Noninvasive Continuous Cardiac Output by the Clearsight® With Invasive Monitoring by PICCO® in Abdominal Major Surgery</brief_title>
  <acronym>CLEARPICCO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      In high-risk patients, it is now recommended to guide the intraoperative volume replacement&#xD;
      via the stroke volume.&#xD;
&#xD;
      Today, the most commonly used technique for estimating the stroke volume is the&#xD;
      transpulmonary thermodilution and the arterial waveform analysis in the radial artery by&#xD;
      PICCO®.&#xD;
&#xD;
      This technique has the disadvantage of being invasive and increasing the time dedicated to&#xD;
      anesthesia during the surgery.&#xD;
&#xD;
      The future is the non-invasive monitoring of stroke volume. Thus, Edwards Life Science has&#xD;
      developed a continuous monitoring technology and non-invasive arterial pressure, cardiac&#xD;
      output and stroke volume using a digital sensor (ClearSight®). This continuous monitoring of&#xD;
      blood pressure was validated in cardiothoracic surgery but studies about monitoring cardiac&#xD;
      output or stroke volume are inconclusive and contradictory.&#xD;
&#xD;
      The objective of this study is to compare the use of non-invasive monitoring of stroke volume&#xD;
      by ClearSight® with the transpulmonary thermodilution and the arterial waveform analysis in&#xD;
      radial artery by PICCO® in abdominal major surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2016</start_date>
  <completion_date type="Actual">May 7, 2018</completion_date>
  <primary_completion_date type="Actual">May 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Stroke ejection volume (SEV) measure by ClearSight®</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke ejection volume measure by PICCO®</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <condition>Cardiac Output Measurement</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled to undergo major abdominal surgery&#xD;
&#xD;
          -  Patients monitored by a PICCO® device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with heart rhythm disorder&#xD;
&#xD;
          -  Patients with Raynaud's disease or vasculitis&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Significant edema fingers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Matthieu BOISSON</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

